

Vinaya Simha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7113080/publications.pdf>

Version: 2024-02-01

31
papers

2,703
citations

430874

18
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

2530
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired Muscle Mitochondrial Function in Familial Partial Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 346-362.	3.6	6
2	Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis. <i>Journal of Clinical Lipidology</i> , 2021, 15, 97-103.	1.5	5
3	From tissue to human regeneration: the development of a comprehensive regenerative care clinic for people with diabetes. <i>Regenerative Medicine</i> , 2021, 16, 219-228.	1.7	1
4	Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1655-1669.	3.0	16
5	Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH. <i>Hepatology</i> , 2021, 74, 2897-2898.	7.3	7
6	Management of hypertriglyceridemia. <i>BMJ, The</i> , 2020, 371, m3109.	6.0	89
7	Perioperative Evaluation and Management of Endocrine Disorders. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2760-2774.	3.0	22
8	Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 1822-1828.	8.6	34
9	Glucose Control in the Perioperative Period—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 82.	7.4	0
10	Perioperative Glucose Control in Patients With Diabetes Undergoing Elective Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 399.	7.4	45
11	Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 9-15.	2.4	18
12	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. <i>European Heart Journal</i> , 2016, 37, 3588-3595.	2.2	174
13	HDL Cholesterol Story Is Dead: Long Live HDL!. <i>Diabetes</i> , 2016, 65, 2826-2828.	0.6	3
14	Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial. <i>Journal of Clinical Lipidology</i> , 2016, 10, 627-634.	1.5	17
15	Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 205-212.	2.4	7
16	A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1257-1278.	3.0	35
17	Comparison of Efficacy and Safety of Leptin Replacement Therapy in Moderately and Severely Hypoleptinemic Patients with Familial Partial Lipodystrophy of the Dunnigan Variety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 785-792.	3.6	80
18	Effect of Vitamin D Replacement on Insulin Sensitivity in Subjects With Vitamin D Deficiency. <i>Journal of Investigative Medicine</i> , 2012, 60, 1214-1218.	1.6	11

#	ARTICLE	IF	CITATIONS
19	A unique model for evaluating obesity cardiomyopathy: Can less mean more?. FASEB Journal, 2012, 26, 877.3.	0.5	0
20	Inherited lipodystrophies and hypertriglyceridemia. Current Opinion in Lipidology, 2009, 20, 300-308.	2.7	52
21	Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability. American Journal of Medical Genetics, Part A, 2008, 146A, 2318-2326.	1.2	43
22	Dietary carbohydrates and risk of type 2 diabetes: are rice eaters doomed?. The National Medical Journal of India, 2008, 21, 80-1.	0.3	0
23	Lipodystrophy: lessons in lipid and energy metabolism. Current Opinion in Lipidology, 2006, 17, 162-169.	2.7	97
24	Effect of Leptin Replacement on Intrahepatic and Intramyocellular Lipid Content in Patients With Generalized Lipodystrophy. Diabetes Care, 2003, 26, 30-35.	8.6	115
25	Phenotypic and Genetic Heterogeneity in Congenital Generalized Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4840-4847.	3.6	217
26	Genetic and Phenotypic Heterogeneity in Patients with Mandibuloacral Dysplasia-Associated Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2821-2824.	3.6	120
27	Phenotypic Heterogeneity in Body Fat Distribution in Patients with Congenital Generalized Lipodystrophy Caused by Mutations in the AGPAT2 or Seipin Genes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5433-5437.	3.6	155
28	Body Fat Distribution and Metabolic Derangements in Patients with Familial Partial Lipodystrophy Associated with Mandibuloacral Dysplasia. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 776-785.	3.6	107
29	Effect of Subcutaneous Leptin Replacement Therapy on Bone Metabolism in Patients with Generalized Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4942-4945.	3.6	64
30	Leptin-Replacement Therapy for Lipodystrophy. New England Journal of Medicine, 2002, 346, 570-578.	27.0	1,130
31	Body Fat Distribution and Metabolic Derangements in Patients with Familial Partial Lipodystrophy Associated with Mandibuloacral Dysplasia. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 776-785.	3.6	33